Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Zylo Therapeutics.

    Client Virtual Booth

    ZYLO THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Zylo Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    105A Ben Hamby Rd., Greenville, SC 29615
    Telephone
    Telephone
    858.775.6710
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.zylotherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/in/zylo-therapeutics-2721a5156/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Psychedelics Company Silo Pharma Working on Time-Release and Dosage Ketamine Implant and Topical, Hoping to Deliver Steady Pain Relief for Four Million ...

    Details:

    The agreement aims to create a time-release ketamine implant, SP-26, which blocks the activity of the N-methyl-D-aspartate receptor (NMDAR), to treat fibromyalgia and other chronic pain conditions.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Musculoskeletal Product Name: SP-26

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Silo Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement June 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Silo Pharma and Zylo Enter Into Joint Venture Agreement to Focus on the Development of Ketamine using ZTI’s Z-pod™ Technology

    Details:

    The joint venture will initially explore the clinical development of ketamine using ZTI’s Z-pod technology, but also provides for Silo Pharma to obtain an exclusive option for the clinical development of psilocybin using ZTI’s Z-pod technology as well.


    Lead Product(s): Ketamine Hydrochloride

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Silo Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 28, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model

    Details:

    Results from the study demonstrated that the novel HT-005 loaded Z-pods™ were effective to reduce skin plaques associated with CLE, with statistical significance demonstrated in the overall average skin score as well as individual skin scores on the head and scapula.


    Lead Product(s): HT-005 Z-PODS

    Therapeutic Area: Immunology Product Name: HT-005

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Recipient: Hoth Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 21, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Hoth Therapeutics Reports Positive Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus

    Details:

    The animal study supports that HT-005 has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need.


    Lead Product(s): HT-005 Z-PODS

    Therapeutic Area: Immunology Product Name: HT-005

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Recipient: Hoth Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 03, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search